On the Record · AstraZeneca
AstraZeneca competitors, on the record
The companies whose own annual reports name AstraZeneca as a competitor, each with the sentence it appears in and the filing it came from.
Who AstraZeneca names
AstraZeneca’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names AstraZeneca
Companies whose own annual reports name AstraZeneca as a competitor.
Word for word“AstraZeneca CALQUENCE U.S., Europe, Asia Pacific & China” 10-K for 2025
Word for word“Should the combination of zanzalintinib and nivolumab be approved for the treatment of these RCC patients, we believe its principal competition may include AstraZeneca PLC’s savolitinib + durvalumab vs. Pfizer’s sunitinib and similar approved therapies or therapies in late-stage development that compete with cabozantinib or combination regimens containing cabozantinib in various RCC indications.” 10-K for 2026
Word for word“We are aware of several other FRa ADCs in development, including AbbVie’s next-generation FRa ADC IMGN151; Eli Lilly’s LY4170156; AstraZeneca’s AZD5335; Eiasi’s farletuzumab; and BioThera Solutions’ BAT8006.” 20-F for 2025
Word for word“UPLIZNA faces competition from eculizumab, marketed as Soliris ® by AstraZeneca plc, and satralizumab, marketed as Enspryng TM by Genentech/Chugai Pharmaceuticals Co., Ltd., a subsidiary of F. Hoffmann-La Roche Ltd., each for the treatment of patients with NMOSD.” 10-K for 2022
Word for word“Additionally, there are a number of Phase 3 compounds (dazukibart (anti-IFN; Pfizer), anifrolumab (Saphnelo®; anti-IFN; AstraZeneca) and efartigimod (Vyvgart®; anti-FcRn; Argenx) which could launch before the end of the decade.” 20-F for 2025
Word for word“There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda ® (pembrolizumab), Bristol-Myers Squibb's Opdivo ® (nivolumab), Roche's Tecentriq ® (atezolizumab), AstraZeneca's Imfinzi ® (durvalumab), and Sun Pharma's Unloxcyt ™ (cosibelimab).” 10-K for 2025
Read from AstraZeneca’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.